Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial)
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial)
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 72, Issue 6, Pages 1760-1768
Publisher
Oxford University Press (OUP)
Online
2017-02-15
DOI
10.1093/jac/dkx062
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PEPDar: A randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis
- (2016) G Fätkenheuer et al. HIV MEDICINE
- UK guideline for the use of HIV Post-Exposure Prophylaxis Following Sexual Exposure, 2015
- (2016) Fiona Cresswell et al. INTERNATIONAL JOURNAL OF STD & AIDS
- A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection
- (2016) Lorna Leal et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection
- (2016) Lorna Leal et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial
- (2016) Sheena McCormack et al. LANCET
- Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug–drug interactions (DDIs) with improved adherence and tolerability
- (2016) Larissa Mulka et al. SEXUALLY TRANSMITTED INFECTIONS
- Transitioning to HIV Pre-Exposure Prophylaxis (PrEP) from Non-Occupational Post-Exposure Prophylaxis (nPEP) in a Comprehensive HIV Prevention Clinic: A Prospective Cohort Study
- (2015) Reed A.C. Siemieniuk et al. AIDS PATIENT CARE AND STDS
- Choice of Antiretroviral Drugs for Postexposure Prophylaxis for Adults and Adolescents: A Systematic Review
- (2015) N. Ford et al. CLINICAL INFECTIOUS DISEASES
- Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men
- (2015) Rosalind Foster et al. CLINICAL INFECTIOUS DISEASES
- Sexually transmitted infections and viral hepatitides in patients presenting for non-occupational HIV post-exposure prophylaxis: results of a prospective cohort study
- (2015) Nirojini Sivachandran et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Fanconi Syndrome Accompanied by Renal Function Decline with Tenofovir Disoproxil Fumarate: A Prospective, Case-Control Study of Predictors and Resolution in HIV-Infected Patients
- (2014) Samir K. Gupta et al. PLoS One
- Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana
- (2012) Michael C. Thigpen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine
- (2011) Vicens Diaz–Brito et al. ANTIVIRAL THERAPY
- UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure (2011)
- (2011) P Benn et al. INTERNATIONAL JOURNAL OF STD & AIDS
- Single and Multiple Dose Pharmacokinetics of Maraviroc in Saliva, Semen, and Rectal Tissue of Healthy HIV-Negative Men
- (2011) Kevin C. Brown et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study
- (2010) Juan Sierra-Madero et al. HIV CLINICAL TRIALS
- Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2
- (2010) W David Hardy et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection
- (2010) David A. Cooper et al. JOURNAL OF INFECTIOUS DISEASES
- Protection of Rhesus Macaques from Vaginal Infection by Vaginally Delivered Maraviroc, an Inhibitor of HIV‐1 Entry via the CCR5 Co‐Receptor
- (2010) Ronald S. Veazey et al. JOURNAL OF INFECTIOUS DISEASES
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
- (2010) Robert M. Grant et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiretroviral drug concentrations in the male and female genital tract: implications for the sexual transmission of HIV
- (2010) Stephen Taylor et al. Current Opinion in HIV and AIDS
- Tenofovir DF Plus Lamivudine or Emtricitabine for Nonoccupational Postexposure Prophylaxis (NPEP) in a Boston Community Health Center
- (2009) Kenneth H Mayer et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Once-Daily Lopinavir/Ritonavir-Based Regimen Is Noninferior to Twice-Daily Dosing and Results in Similar Safety and Tolerability in Antiretroviral-Naive Subjects Through 48 Weeks
- (2009) Joseph Gathe et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Maraviroc for Previously Treated Patients with R5 HIV-1 Infection
- (2008) Roy M. Gulick et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started